What question did this study set out to answer?

Characterize and compare the in vitro antifungal susceptibility profiles of Cryptococcus neoformans isolates across diverse international clinical settings.

January 1, 2004Emerging infectious diseasesOpen Access

Antifungal Susceptibilities ofCryptococcus neoformans

View Full Paper

Ask AI

Bookmark

Characterize and compare the in vitro antifungal susceptibility profiles of Cryptococcus neoformans isolates across diverse international clinical settings.
Measured minimum inhibitory concentrations (MICs) for amphotericin B, 5-flucytosine, fluconazole, itraconazole, and ketoconazole.
Evaluated clinical isolates collected from Thailand, Malawi, and the United States.
Demonstrated no evidence of antifungal resistance among the evaluated isolates for any of the tested drugs.
Showed no observable differences in MIC susceptibility distributions across the three countries.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

In vitro susceptibility study demonstrates consistent antifungal profiles across Cryptococcus neoformans clinical isolates, indicating standard therapies remain broadly effective.

Cite This Study

Archibald et al. (2004) studied this question.

synapsesocial.com/papers/6aaf9dab3d3654015adcbc92 https://doi.org/10.3201/eid1001.020779

View Full Paper

Ask AI

Bookmark

Implication

In vitro susceptibility study demonstrates consistent antifungal profiles across Cryptococcus neoformans clinical isolates, indicating standard therapies remain broadly effective.

Antifungal Susceptibilities ofCryptococcus neoformans

Key Points

Discussion

Implication

Cite This Study

Antifungal Susceptibilities ofCryptococcus neoformans

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider